title: Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
abstract: BACKGROUND
  Serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) is a metabolite of type I collagen comprising 90% or more of organic substances in bone. Its usefulness as a marker of bone metastasis from malignant tumors is expected.
  
  
  METHODS
  We measured ICTP to evaluate its clinical usefulness for diagnosis of bone metastasis in 140 patients with lung cancer. For comparison, serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-1), gastrin-releasing peptide precursor (ProGRP), alkaline phosphatase and calcium were simultaneously measured. ICTP was measured by double-antibody radioimmunoassay.
  
  
  RESULTS
  ICTP was significantly higher in patients with bone metastasis from lung cancer than in the group without bone metastasis, patients with other pulmonary diseases or healthy control subjects and showed excellent sensitivity and specificity, indicating that this marker is highly useful for complementary diagnosis of bone metastasis from lung cancer. Moreover, the survival duration was significantly shorter in the ICTP-positive group than in the ICTP-negative group, suggesting that ICTP can be a prognostic factor in lung cancer.
  
  
  CONCLUSIONS
  It is suggested that measurement of ICTP is worthwhile as a serological diagnostic method of bone metastasis from lung cancer. Moreover, since repeated measurements are possible, this measure was considered very helpful in complementary diagnosis of bone metastasis and also as a standard to determine the timing of examinations such as bone scintigraphy.
authors.affiliation: Department of Internal Medicine, Fujita Health University School of Medicine, Second Hospital, Nagoya, Aichi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Horiguchi
authors.forename: S
authors.initials: S
authors.lastname: Tachikawa
authors.forename: R
authors.initials: R
authors.lastname: Kondo
authors.forename: M
authors.initials: M
authors.lastname: Hirose
authors.forename: S
authors.initials: S
authors.lastname: Teruya
authors.forename: A
authors.initials: A
authors.lastname: Ishibashi
authors.forename: K
authors.initials: K
authors.lastname: Banno
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D000951:Antigens, Neoplasm / Q000097:blood; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary*; D002118:Calcium / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D018287:Carcinoma, Large Cell / Q000097:blood / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000097:blood / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000556:secondary; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D005260:Female; D005768:Gastrointestinal Hormones / Q000097:blood; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D011994:Recombinant Proteins / Q000097:blood; D012680:Sensitivity and Specificity; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D024042:Collagen Type I; D005768:Gastrointestinal Hormones; D053539:Keratin-19; D010446:Peptide Fragments; D010455:Peptides; D011994:Recombinant Proteins; C102012:antigen CYFRA21.1; C052929:collagen type I trimeric cross-linked peptide; C087079:pro-gastrin-releasing peptide (31-98); D007633:Keratins; D003094:Collagen; D000469:Alkaline Phosphatase; D002118:Calcium